Hodgkin's lymphoma
Hodgkin's lymphoma or malignant lymphogranuloma, is a cancer of the lymphatic tissue. The etiology is unknown (genetic predisposition, immune disorders, EBV, HIV ). It is most often diagnosed between the ages of 20 and 30, and the incidence rises again after the age of 50. The disease begins in lymph nodes (most often in the axial distribution), from where it spreads to neighboring nodes as well as to the systemic circulation.
Histologically, they are divided according to the number of Reed-Sternberg cells (abnormal cells derived from B lymphocytes) and according to the degree of cellular response:
- type I: predominance of lymphocytes (few RS cells, many lymphocytes: best prognosis) (5%);
- type II: nodular-sclerotic (nodular foci, cells (reticular, lymphocytes, histiocytes) in collagen fibers) (70%);
- type III: mixed (20-25%);
- type IV: classic, lymphocyte-poor (Sternberg cells proliferated; worst prognosis) (1%).
Clinical picture[edit | edit source]
- Painless enlargement of the nodes (cervical, axillary, inguinal);
- fever (Pel–Ebstein fever), itching, sweating, malaise, fatigue, weight loss;
- splenomegaly;
- cough, dyspnea, superior vena cava syndrome (mediastinal involvement);
- effusion, infiltration of parenchymal organs and skeleton (in advanced disability).
Diagnosis[edit | edit source]
- Nodular extirpation and its subsequent histopathological examination - the presence of RS cells or Hodgkin's cells (RS cell precursors);
- chest x-ray, abdominal US, scintigraphy of the liver and spleen, CT and lymphography , PET;
- trepano-biopsy of the bone marrow
Stages[edit | edit source]
- Stage I (involvement of one lymphatic area or one extralymphatic organ);
- stage II (affecting two or more areas on one side of the diaphragm);
- stage III (involvement of lymph nodes on both sides of the diaphragm, including an extralymphatic organ or spleen);
- stage IV (disseminated involvement of extralymphatic organs independent of nodal involvement).
- Furthermore, each stage is divided into A and B:
- A - the patient is without general symptoms;
- B - with general symptoms (weight loss of 10% in 6 months, fever more than 38 ° C, night sweats)
Complications[edit | edit source]
- Infections
- Spinal cord compression when affecting the vertebrae.
Therapy[edit | edit source]
The basic treatment modality is systemic treatment in the form of combined chemotherapy, in localized stages we supplement it with radiotherapy. Basic regimens used: ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) and BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone).
- Localized (early) stages I, II: if with favorable prognosis (without risk factors), 2 × ABVD and 20 Gy radiotherapy. If with unfavorable prognosis (with risk factors), 2 × BEACOPP + 2 × ABVD and 20 Gy radiotherapy.
- Advanced Stages III, IV: 6 × BEACOPP
- In case of relapse - a rescue regimen (based on platinum derivatives), autologous transplantation .
- New drugs are being used to treat relapses: brentuximab vedotin (anti-CD30 antibody)[1]
Prognosis[edit | edit source]
Patients have a good prognosis: about 70-80% of patients recover. The tumor has good curability.
References[edit | edit source]
Related articles[edit | edit source]
- Malignant lymphoma
- Non-Hodgkin's malignant lymphomas
- Diffuse large B-cell lymphoma
- Leukemia
- Chemotherapy
- Radiotherapy
Citations[edit | edit source]
- ↑ ČEŠKA, Richard, et al. Interna. 2. vydání. Praha : Triton, 2015. 909 s. ISBN 978-80-7387-895-5.
Literature[edit | edit source]
- CZECH, Richard, et al. Internal. 2nd edition. Prague: Triton, 2015. 909 pp. ISBN 978-80-7387-895-5 .
- KLENER, Pavel, et al. Internal Medicine. 4th edition. Prague: Galén, Karolinum, 2011. 1174 pp. ISBN 978-80-7262-705-9 .